Similarly, Cortes-Hernandez et al. [51] reported preliminary results of a phase I/II trial of YTB323 a rapidly manufactured CD19 CAR-T for the treatment of refractory SLE, 3 patients with efficacy data showed reductions in SLEDAI scores and improvement in biomarkers. This evidence concerns the gene CD19 and systemic lupus erythematosus.